Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter Platform Trial of Targeted Immunomodulator Therapies for Moderate to Severe Atopic Dermatitis

NCT06718101 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06718101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06718101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter Platform Trial of Targeted Immunomodulator Therapies for Moderate to Severe Atopic Dermatitis
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 19, 2024
Completion date
May 31, 2027
Enrollment
83 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis